Lilly’s Alzheimer’s drug donanemab passes PhIII trial – Endpoints News – Endpoints News

Leave a Comment / Business / By
  1. Lilly’s Alzheimer’s drug donanemab passes PhIII trial – Endpoints NewsTerminal News
  2. Donanemab, Eli Lilly’s Alzheimer’s treatment, slowed disease progression in clinical trialCNBC
  3. Experimental Alzheimer’s drug slows cognitive decline in large trial, drugmaker Eli Lilly saysCNN
  4. Eli Lilly Stock jumps on positive data from Alzheimer’s drug’s Phase 3 trialbarrons
  5. Lilly’s donanemab significantly slowed cognitive and functional decline in a phase 3 study in early-onset Alzheimer’s diseasePR Newswire
  6. See full coverage on Google News

Leave a Comment

Your email address will not be published. Required fields are marked *